Soluble tumor necrosis factor receptor 1 and 2 (sTNFR1/2)

Soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and sTNFR2) are the circulating, extracellular domains of the membrane-bound receptors TNFRSF1A and TNFRSF1B, respectively. These soluble forms are primarily generated through proteolytic cleavage (shedding) of the cell-surface receptors by the metalloproteinase ADAM17, also known as TACE [UniProt P19438; UniProt P20333]. Biologically, sTNFRs function as natural endogenous antagonists by acting as decoy receptors that sequester TNF-alpha and TNF-beta, thereby modulating the intensity of the inflammatory response and protecting cells from excessive TNF-mediated apoptosis [PubMed: 10603367]. In clinical medicine, elevated levels of these soluble receptors are highly validated biomarkers for the progression of diabetic kidney disease and are associated with increased mortality in patients with heart failure [PubMed: 22237745]. The therapeutic utility of this mechanism is exemplified by Etanercept, a recombinant fusion protein consisting of the sTNFR2 extracellular domain linked to an IgG1 Fc fragment, which is widely used to treat autoimmune conditions like rheumatoid arthritis and plaque psoriasis [DrugBank DB00005]. While effective at dampening pathological inflammation, pharmacological modulation of these pathways requires careful monitoring due to the risk of immunosuppression and opportunistic infections [StatPearls: TNF Inhibitors].

Other names

sTNF-R1sTNF-R2Soluble tumor necrosis factor receptor superfamily member 1ASoluble tumor necrosis factor receptor superfamily member 1BTumor necrosis factor-binding protein 1Tumor necrosis factor-binding protein 2TBPITBPII

Acts as a decoy receptor that binds and neutralizes circulating tumor necrosis factor (TNF-alpha and TNF-beta), preventing these ligands from binding to cell-surface receptors and initiating pro-inflammatory signaling cascades.